Summary: Protealis has achieved a major double milestone for European soybean production: receiving EU regulatory approval for its proprietary MagNfix™ inoculant seed coating and registering five new high-performance soybean varieties. These advancements, including the first ultra-early 0000 variety for France and a commercial launch in Poland, provide an integrated “ready-to-sow” solution designed specifically for northern European climates.
Protealis Secures EU Approval for MagNfix™ Inoculant and Expands Soybean Portfolio
Ghent, Belgium — March 5, 2026
Protealis, the European specialist in non-GMO legume seeds and technologies, today announced several milestones strengthening its position in the fast-growing European soybean market. The company has obtained European regulatory approval (FPR 2019/1009) for MagNfix™, its first biological solution. This proprietary inoculant seed coating is designed to support higher soybean yield and protein content through a specialized Bradyrhizobium bacteria strain adapted to European soils.
In independent registration trials, MagNfix™ demonstrated average yield increases of +31% and a +7% improvement in protein content compared to peers. Delivered as a ready-to-sow coated seed, it eliminates the need for on-farm inoculation, providing a scalable solution for large farming operations.
- PRO Hekla (MG 0000, France): The company’s first ultra-early variety suited for colder northern regions.
- PRO Dinara & PRO Katla (MG 000, Poland): Marking entry into a market that has doubled in acreage in two years.
- PRO Erebus (MG 00, Germany): Combines high yield with excellent canopy coverage for natural weed suppression.
- PRO Bingo (MG 000, Belgium): Focused on a strong yield-protein balance and excellent canopy closure.
“This is a pivotal moment,” said Benjamin Laga, CEO of Protealis. “For years, soybean growth in Europe was constrained by a lack of varieties adapted to colder climates. Protealis has addressed this by combining climate-adapted genetics and advanced breeding technologies—including AI-driven selection—with our proprietary MagNfix™ inoculant.”
David Buckeridge, Chairman of the Board, added that the combination of advanced genetics and biologicals supports the economic viability of soybean cultivation in northern regions, boosting Europe’s domestic plant protein production in a way that works for farmers both economically and agronomically.
Following this approval, Protealis will initiate a phased pre-commercial rollout in Poland, France, and Germany during the current season, ahead of a broader commercial launch in 2027.
Leave a Reply